Outlook: Intervention is part of the cure
BTG is transforming itself into a leading Interventional Medicine (IM) player. IM revenue as a percentage of the total was 27% for H115 vs 19% in H114, and the company has since acquired PneumRx. BTG now has five commercial-stage IM products targeting the fast-growing interventional oncology, vascular and respiratory markets. Management is targeting IM revenues of $1.25bn+ for 2021 through organic growth, highlighting the attractiveness of the IM market. BTG also aims to expand its Specialty Pharma business, and actively looks at M&A opportunities.BTG is engaged in the business of healthcare which focusing on Interventional Medicine therapies for cancer, severe emphysema, severe bloodclots and varicose veins, and Specialty Pharmaceuticals for acute care uses, and a licensing business. Co. manufactures a number of products in-house including the Bead products, the EKOS Endovascular System, Varithena®, the PneumRx® Coil, the GALIL™ Cryoablation Solutions, and the polyclonal antibodies CroFab® and DigiFab®. The EKOS® System is an ultrasonic catheter drug delivery device used in the treatment of blood clots, and Varithena® is a proprietary engineered microfoam used in the treatment of varicose veins.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.